Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes

被引：0
|
作者：
Edith M. Heintjes
Trine L. Thomsen
Fernie J. A. Penning-van Beest
Torsten E. Christensen
Ron M. C. Herings
机构：
[1] PHARMO Institute,Department of Health Policy & Management
[2] Novo Nordisk A/S,undefined
[3] Erasmus University Rotterdam,undefined
来源：
Advances in Therapy | 2010年 / 27卷
关键词：
dose; glycemic control; HbA1c; insulin detemir; insulin glargine; retrospective cohort study; type 2 diabetes; utilization;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：211 / 222
页数：11
相关论文
共 50 条
  • [21] Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study
    Davies, M. J.
    Donnelly, R.
    Barnett, A. H.
    Jones, S.
    Nicolay, C.
    Kilcoyne, A.
    [J]. DIABETES OBESITY & METABOLISM, 2009, 11 (12): : 1153 - 1162
  • [22] Insulin therapy in type 2 diabetes:: role of the long-acting insulin glargine analogue
    Yki-Järvinen, H
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2004, 34 (06) : 410 - 416
  • [23] Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Patients With Type 1 Diabetes
    Rosenstock, Julio
    Bergenstal, Richard M.
    Blevins, Thomas
    Morrow, Linda A.
    Prince, Melvin J.
    Qu, Yongming
    Sinha, Vikram P.
    Howey, D. C.
    Jacober, Scott J.
    [J]. DIABETES, 2012, 61 : A263 - A263
  • [24] Cardiovascular mortality in type 2 diabetes patients with incident exposure to long-acting insulin analogues
    Ioacara, S.
    Guja, C.
    Ionescu-Tirgoviste, C.
    Fica, S.
    Reghina, A.
    Georgescu, O.
    Roden, M.
    [J]. DIABETOLOGIA, 2013, 56 : S88 - S88
  • [25] Insulin glargine: long-acting basal insulin analog for improved metabolic control
    Gerich, JE
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (01) : 31 - 37
  • [26] The effect of long-acting insulin analogues, glargine or detemir, in Type 2 diabetes
    Dissanayake, S.
    Balakrisna-Rao, P.
    Ahmed, A. B.
    [J]. DIABETIC MEDICINE, 2007, 24 : 75 - 75
  • [27] POSTPRANDIAL GLYCEMIC EFFECTS OF A LONG-ACTING SOMATOSTATIN ANALOG (OCTREOTIDE) IN NON-INSULIN DEPENDENT DIABETES-MELLITUS
    WILLIAMS, G
    FUESSL, HS
    BURRIN, JM
    CHILVERS, E
    BLOOM, SR
    [J]. HORMONE AND METABOLIC RESEARCH, 1988, 20 (03) : 168 - 170
  • [28] Preference in time of insulin injection in type 2 diabetic patients treated with once-daily long-acting insulin analog
    Takahara, M.
    Shiraiwa, T.
    Katakami, N.
    Matsuoka, T. A.
    Shimomura, I.
    [J]. DIABETES OBESITY & METABOLISM, 2016, 18 (11): : 1098 - 1099
  • [29] The Use of Long-Acting Insulin Analogues and the Risk of Colorectal Cancer in Patients with Type 2 Diabetes Mellitus
    Pradhan, Richeek
    Yin, Hui
    Yu, Oriana HoiYun
    Azoulay, Laurent
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 52 - 52
  • [30] Long-Acting Insulin Analogs: A Review of "Real-World" Effectiveness in Patients with Type 2 Diabetes
    Pollock, Richard F.
    Erny-Albrecht, Katrina M.
    Kalsekar, Anupama
    Bruhn, David
    Valentine, William J.
    [J]. CURRENT DIABETES REVIEWS, 2011, 7 (01) : 61 - 74
12345